In summary, over the last ten years the most impressive advantage has become obtained in HER2/neu-overexpressing MBC. Introduction of bevacizumab being a VEGF-directed focused therapy stays an issue on debate. Some of the novel therapeutics on the breast cancer armamentarium resulted in prolongation of survival for people with MBC. At this time, fa